

March 28, 2013



ResMed Takes Action to Enforce Patents

Suit Filed against APEX Medical Corp. for Patent Infringement on Devices and Masks

SAN DIEGO, March 28, 2013 /PRNewswire/ -- ResMed, an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has filed parallel legal actions in the International Trade Commission (ITC) and in U.S. federal court to stop the infringement of ResMed patents.

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

ResMed filed the actions against Taiwanese manufacturer APEX Medical and its U.S. distributor, Medical Depot, Inc., doing business as Drive Medical Design and Manufacturing. ResMed alleges that multiple ResMed patents are infringed by several APEX products, including:

- The APEX WIZARD 210 and WIZARD 220 masks
- The identical Freedom 210 and Freedom 220 masks made by APEX and sold by Medical Depot
- The APEX iCH and XT Fit flow generators

ResMed is asking the ITC to stop the importation and sales of these products in the United States, and it is asking the U.S. federal court to stop the infringement and award damages against the defendants.

"For more than two decades, ResMed has generated significant advances in innovative products for sleep-disordered breathing therapy," said ResMed global general counsel and chief administrative officer David Pendarvis. "We invest over a hundred million dollars in research and development each year to fuel these advances and other companies should not be allowed to infringe ResMed's intellectual property by using our technology."

About ResMed:

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

Gretchen Griswold
Director, Global Corporate Communications
O: 858-836-6789
news@resmed.com

For the Finance and Investor Community

Constance Bienfait
Director, Investor Relations
O: 858-836-5971
constance.bienfait@resmed.com

SOURCE ResMed Inc.